4.4 Review

Adenosine as a neuromodulator in neurological diseases

Journal

CURRENT OPINION IN PHARMACOLOGY
Volume 8, Issue 1, Pages 2-7

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2007.09.002

Keywords

-

Funding

  1. NINDS NIH HHS [R01 NS047622, R01 NS047622-01A2] Funding Source: Medline

Ask authors/readers for more resources

Adenosine is a modulator of brain function uniquely positioned to integrate excitatory and inhibitory neurotransmission. The past few years brought a wealth of new data fostering our understanding of how the adenosine system is involved in the pathogenesis of neurological diseases. Thus, dysregulation of the adenosine system is implicated in epileptogenesis and cell therapies have been developed to locally augment adenosine in an approach to prevent seizures. While activation of inhibitory adenosine A, receptors is beneficial in epilepsy, chronic pain and cerebral ischemia, inhibition of facilitatory A(2A) receptors has profound neuroprotective effects, which are currently exploited in clinical trials in Parkinson's disease. A new era of adenosine-based therapies has begun, with the prospect to cover a wide range of neurological diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available